- Home
- CLLS vs KLRS Comparison
CLLS vs KLRS Comparison
Compare CLLS & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- KLRS
- Stock Information
- Founded
- CLLS 1999
- KLRS 2019
- Country
- CLLS France
- KLRS United States
- Employees
- CLLS N/A
- KLRS N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLLS Health Care
- KLRS Health Care
- Exchange
- CLLS Nasdaq
- KLRS Nasdaq
- Market Cap
- CLLS 144.4M
- KLRS 129.0M
- IPO Year
- CLLS 2007
- KLRS N/A
- Fundamental
- Price
- CLLS $1.58
- KLRS $3.48
- Analyst Decision
- CLLS Buy
- KLRS Buy
- Analyst Count
- CLLS 3
- KLRS 1
- Target Price
- CLLS $7.00
- KLRS N/A
- AVG Volume (30 Days)
- CLLS 79.4K
- KLRS 62.3K
- Earning Date
- CLLS 05-27-2025
- KLRS 05-19-2025
- Dividend Yield
- CLLS N/A
- KLRS N/A
- EPS Growth
- CLLS N/A
- KLRS N/A
- EPS
- CLLS N/A
- KLRS N/A
- Revenue
- CLLS $49,217,000.00
- KLRS N/A
- Revenue This Year
- CLLS $48.52
- KLRS N/A
- Revenue Next Year
- CLLS $5.17
- KLRS N/A
- P/E Ratio
- CLLS N/A
- KLRS N/A
- Revenue Growth
- CLLS 435.38
- KLRS N/A
- 52 Week Low
- CLLS $1.10
- KLRS $4.19
- 52 Week High
- CLLS $3.32
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- CLLS 60.44
- KLRS N/A
- Support Level
- CLLS $1.46
- KLRS N/A
- Resistance Level
- CLLS $1.65
- KLRS N/A
- Average True Range (ATR)
- CLLS 0.08
- KLRS 0.00
- MACD
- CLLS -0.00
- KLRS 0.00
- Stochastic Oscillator
- CLLS 75.00
- KLRS 0.00
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.